Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.
Methods: Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [Zr]Zr-PSMA-617 PET/CT post-negative [Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.
Results: [Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.
Limitations: retrospective, single center design; infrequent histopathological and imaging verification.
Conclusion: This large series provides further evidence that [Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457487 | PMC |
| http://dx.doi.org/10.1186/s40644-024-00778-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT.
Clin Nucl Med
February 2025
From the Department of Nuclear Medicine, Saarland University, Homburg, Germany.
We report an interesting case of a 64-year-old man with a history of radical prostatectomy for prostate cancer. The patient presented with steady increasing prostate-specific antigen levels, but with negative findings on previous multiple conventional prostate-specific membrane antigen (PSMA) PET/CT (with [68Ga]Ga-PSMA-11) and [18F]FDG PET/CT. A recently introduced PSMA tracer using long-lived 89Zr (half-life 3.
View Article and Find Full Text PDF[Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [F]PSMA-1007 Imaging.
Diagnostics (Basel)
October 2024
Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany.
We report a case of a 79-year-old male patient with a history of radical prostatectomy for prostate cancer. The patient presented with biochemical reoccurrence; however, previous conventional PSMA PET/CT using [F]PSMA-1007 showed two indetermined findings with low uptake in the right iliac lymph nodes. Further MRI evaluation provided no additional information.
View Article and Find Full Text PDFOutstanding increase in tumor-to-background ratio over time allows tumor localization by [Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
Cancer Imaging
October 2024
Departments of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Article Synopsis
- A study analyzed 38 men with biochemical recurrence (BCR) of prostate cancer, using a specialized PET/CT imaging technique to track prostate-specific membrane antigen (PSMA) with zirconium-89 radiotracers after prior negative scans.* -
- The results showed that the new imaging method detected a total of 57 lesions, including local recurrences and metastases, in 78% of patients, with significant improvement in tumor visibility over time.* -
- The study concludes that zirconium-89 PSMA PET/CT is effective for identifying early BCR and suggests that the imaging technique outperforms conventional methods, with no noted side effects and a decrease in prostate-specific antigen levels in treated patients.*
[Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
Cancer Imaging
February 2024
Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Background: The state-of-the-art method for imaging men with biochemical recurrence of prostate cancer (BCR) is prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) with tracers containing short-lived radionuclides, e.g., gallium-68 (Ga; half-life: ∼67.
View Article and Find Full Text PDFDetection efficacy of [Zr]Zr-PSMA-617 PET/CT in [Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
Eur J Nucl Med Mol Imaging
July 2023
Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.
Rationale: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 (Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides.
Materials And Methods: To confirm [Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [Zr]Zr-PSMA-617 uptake and lesion-to-background ratio.